Clinical Research Directory
Browse clinical research sites, groups, and studies.
Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Summary
The aim of this observational study is to investigate the survival differences among patients with non-small cell lung cancer who received different adjuvant treatments after neoadjuvant immunotherapy, and to identify the main clinical characteristics of these survival differences. The main question it aims to answer is: 1. Is there a difference in survival between patients who achieve pCR after neoadjuvant immunotherapy and those who do not receive adjuvant therapy? 2. What are the recurrence patterns and high-risk factors for recurrence in patients with pCR after neoadjuvant immunotherapy, and how can early intervention be carried out? 3. Is there a difference in survival among patients with non-MPR after neoadjuvant immunotherapy when they receive different adjuvant treatment modalities (single immunotherapy, chemio-immunotherapy, chemotherapy, etc.)? 4. Should patients with non-MPR after neoadjuvant immunotherapy continue immunotherapy, and what are the predictive markers for receiving adjuvant therapy?
Official title: Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy:A Real World Multicenter Retrospective Study
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
OBSERVATIONAL
Enrollment
10000
Start Date
2020-01-01
Completion Date
2027-12-01
Last Updated
2025-12-01
Healthy Volunteers
Not specified
Conditions
Interventions
PD-1 Inhibitors
Adjuvant PD-1 inhibitor maintenance therapy
Chemotherapy
Postoperative chemotherapy as an adjuvant treatment
PD-1 inhibitors combined with chemotherapy
Postoperative PD-1 inhibitor combined with chemotherapy as adjuvant therapy
Locations (1)
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China